WiLab

WiLab, officially known as Wuhan WiLab Biotechnology, is a high-tech enterprise focused on the development and application of single-cell microfluidic technology for drug discovery. The company's core platform facilitates high-throughput screening and functional analysis of individual immune cells, significantly accelerating the identification of therapeutic antibodies and TCR-T candidates. By utilizing proprietary microfluidic chips and automated imaging, WiLab enables the direct screening of primary B cells and T cells to find rare, high-affinity candidates. Their technology is particularly effective for challenging targets such as GPCRs and ion channels, which are often difficult to address with traditional methods. WiLab serves as a strategic partner for pharmaceutical companies, providing integrated solutions from single-cell sequencing to lead optimization. The company is headquartered in Wuhan, China, and has received significant backing from prominent venture capital firms in the life sciences sector.